A phase I multicenter study of continuous oral administration of lonafarnib (SCH 66336) and intravenous gemcitabine in patients with advanced cancer.

Journal Article

We conducted a phase I study to assess safety, pharmacokinetics, pharmacodynamics, and activity of lonafarnib plus gemcitabine. Subjects received oral lonafarnib twice daily and gemcitabine on days 1, 8, and 15 every 28 days; multiple dose levels were explored. Lonafarnib had no apparent effect on gemcitabine PK. Mean lonafarnib half-life ranged from 4 to 7 hr; median T(max) values ranged from 4 to 8 hr. Two patients had partial response; seven patients had stable disease at least 6 months. Oral lonafarnib at 150 mg a.m./100 mg p.m. plus gemcitabine at 1,000 mg/m(2) is the maximum tolerated dose with acceptable safety and tolerability.

Full Text

Duke Authors

Cited Authors

  • Wong, NS; Meadows, KL; Rosen, LS; Adjei, AA; Kaufmann, SH; Morse, MA; Petros, WP; Zhu, Y; Statkevich, P; Cutler, DL; Meyers, ML; Hurwitz, HI

Published Date

  • November 2011

Published In

Volume / Issue

  • 29 / 9

Start / End Page

  • 617 - 625

PubMed ID

  • 22011284

Electronic International Standard Serial Number (EISSN)

  • 1532-4192

Digital Object Identifier (DOI)

  • 10.3109/07357907.2011.621912

Language

  • eng

Conference Location

  • England